Australian Autoimmune Haemolytic Anaemia (AIHA) Therapeutics Market: Segmented by Diagnosis, Treatment, Distribution Channels, and End Users Size, Share, Impact, Growth, Trends, and Forecasts (2020 2028F)
- Published Date: 2022-12-28
- Report ID: 139985
- Pages: 200
-
Format:
Report Overview
The Australian Autoimmune Haemolytic Anaemia (AIHA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Autoimmune Haemolytic Anaemia (AIHA) is an autoimmune disorder characterised by the premature destruction of healthy red blood cells (RBCs) by auto-antibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37C. Normally, red blood cells live in the body for 100 to 120 days. However, in severe cases of AIHA, the cells may remain only for a few days. In children, it is a rare condition that is usually temporary. In some adults, however, AIHA can be a long-term condition that returns frequently. AIHA can develop rapidly or over time. A decreased number of red blood cells (anemia) may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea).
Recently in June, 2020, 5 cases of AIHA were reported in Australia. Serologically, cases are divided into warm, cold (cold haemagglutinin disease and paroxysmal cold haemoglobinuria) or mixed AIHA.
Market Drivers
The market for Autoimmune Haemolytic Anaemia (AIHA) is primarily driven by a rise in the usage of medications for patients with Autoimmune Haemolytic Anaemia, such as corticosteroids. Because of the fast growing geriatric population, the prevalence of AIHA is increasing. Because the older population has a lower immune system, they are more susceptible to diseases, which fuels market growth. The steady increase in the use of immunoglobulin for treatment of off-label indications is expected to drive the market during the forecast period. Technological improvements in the production and purification methods of intravenous immunoglobulins (IVIG) have made these safer and free from protein, viral, or any other contaminants. This has increased clinician preference for usage of IVIG. This in turn, boosts the market growth during the forecast period.
When compared to materials and methods utilised in the production of traditional pharmaceutical goods, plasma collection and manufacturing methods are expensive. Furthermore, because Intravenous Immunoglobulin (IVIG) products are obtained from blood, more sophisticated collection, purification, and storage processes are necessary.
1. Australian AIHA Therapeutics Market Overview...
A. Market Size
2. Market Growth Drivers.....
A. Increase in Disease Burden of Autoimmune Haemolytic Anaemia (AIHA)
B. Increase in Geriatric Population Fosters the Market Growth
C. Rise in demand for the Development of Combination Therapies
3. Major Types of AIHA.
A. Primary AIHA
B. Secondary AIHA
C. Warm AIHA
D. Cold AIHA
E. Mixed AIHA
4. AIHA Therapeutics Market Segmentation..........................................
A. By Diagnosis
I. Coombs Test
II. Bilirubin Test
III. Haptoglobin Test
IV. Reticulocyte Count
V. Peripheral Smear
VI. Cold Agglutinin Titre
B. By Treatment
I. Corticosteroids
II. Intravenous Immunoglobulins (IVIG)
III. Monoclonal Antibodies
IV. Immunosuppressants
V. Blood Transfusion
VI. Splenectomy (Surgery)
C. By Distribution Channels
I. Retail Pharmacies
II. Hospital Pharmacies
III. Online Pharmacies
D. By End Users
I. Hospitals and Clinics
II. Homecare
III. Speciality Centres
IV. Others
5. AIHA Major Drugs Market Share
A. Market Analysis, Insights and Forecast By Revenue Type
6. Competitive Landscape...
A. Major Players
B. Products in Pipeline
7. Key Company Profiles.
A. Pfizer Company overview, Product & Services, Strategies & Financials
B. Roche Company overview, Product & Services, Strategies & Financials
C. Kezar Company overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape...
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth..
A. New Trends and Development of AIHA therapeutics market
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
